Back to School: How biopharma can reboot drug development. Access exclusive analysis here

VEGF-2: Phase I/II

Researchers reported on a Phase I/II dose escalation study of VEGF-2 gene therapy in 30 patients with stable and refractory exertional angina

Read the full 224 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE